ClinicalTrials.gg
RecruitingNCT06044675Updated Aug 19, 2026

MDMA-Assisted CBCT for PTSD vs CBCT RCT

A Phase 2 interventional study of MDMA assisted psychotherapy and Psychotherapy in Post Traumatic Stress Disorder, sponsored by Remedy. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Remedy · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Stress Disorders, Post-Traumatic with a site in Canada — 34 open to participants now, 42 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.

Planned enrollment
48th of 113
60 · median 54
Started
2024
with 6 others
Phase 2
16 of 127
4 open now
Primary completion
2027-03
later than 22 of 41 live
Registered
101st of 127
by date

Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 48th largest by planned enrollment of the 113 interventional ones that give a count, is one of 7 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 22 of the 41 other live ones, and was the 101st registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

34 of the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, feasibility, acceptability, and effectiveness of MDMA-assisted Cognitive-Behavioral Conjoint Therapy (CBCT) versus CBCT alone for the treatment of Post-Traumatic Stress Disorder (PTSD). PTSD is a debilitating condition that significantly impacts interpersonal relationships and the functioning of individuals and their loved ones. There is also a well-established reciprocal relationship between interpersonal relationships, PTSD, and recovery.

CBCT is a manualized treatment for PTSD that simultaneously addresses PTSD symptoms and relationship satisfaction. It provides dyads with behavioral tools to navigate PTSD-related challenges, as well as the knowledge behind PTSD and how it impacts relationships. Previous research has demonstrated the efficacy of CBCT in improving PTSD symptoms, partner functioning, and relationship satisfaction in both distressed and non-distressed dyads.

MDMA is a drug commonly used recreationally that has been increasingly studied because of its ability to reduce the impact of PTSD symptoms. The effects of MDMA are reduced fear, enhanced communication, trust and introspection, and increased empathy and compassion. The effects of MDMA create a state that enhances the positive effects of therapy by increasing the ability to tolerate negative emotions and allowing clients to stay engaged in therapy without being overwhelmed by the intense emotions surrounding the memories of traumatic events. It is believed that MDMA may help promote the effects of CBCT due to its ability to induce empathy and interpersonal openness.

This randomized study is the second study designed to explore the efficacy of combining MDMA-assisted therapy with CBCT. This study will enroll 30 dyads, where one individual has symptoms of PTSD. Participants will undergo a 7-week psychotherapy course, in MDMA-assisted CBCT or CBCT alone. In the MDMA-assisted CBCT, participants will go through CBCT sessions, and two doses of MDMA will be used as an adjunct to psychotherapy. Participants assigned to the CBCT-only condition will go through CBCT sessions and will have the opportunity to crossover and receive the two MDMA sessions after follow-up. The primary goal of this research is to contribute to the literature on MDMA-assisted CBCT by investigating its feasibility, safety, acceptability, and effectiveness, and by comparing it to active PTSD treatments.

03

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • MDMA
  • Cognitive Behavioural Conjoint Therapy (CBCT)
  • Relationship functioning
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with PTSD

    1. Participant with PTSD
    2. Meet criteria for PTSD
    3. Have a close other person who is able and willing to participate in this study
    4. Are at least 18 years old
    5. Are a resident of Ontario and live within the Greater Toronto Area (GTA)
    6. Are in good physical health
    7. Are proficient in speaking and reading English
    8. Are willing to have all visits audio and video recorded
    9. Are able to swallow pills
    10. Agree to all study rules and commit to all medical and therapy visits
    11. If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist
    12. Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study
    13. Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Therapy Session, and not to drive for at least 24 hours after taking MDMA
    14. Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant
    15. Have a supportive relative, spouse, close friend or other caregiver not participating in this study who can serve as your emergency contact
    16. Agree to inform the researchers within 48 hours of any medical conditions and procedures
    17. Agree to not participate in any other clinical trials during this study
  • Close Significant Other

    1. Have a close other person who meets criteria for PTSD and is able and willing to participate in this study
    2. Are at least 18 years old
    3. Are a resident of Ontario and live within the Greater Toronto Area (GTA)
    4. Are in good physical health
    5. Are proficient in speaking and reading English
    6. Are willing to have all visits audio and video recorded
    7. Are able to swallow pills
    8. Agree to all study rules and commit to all medical and therapy visits
    9. If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist
    10. Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study
    11. Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Therapy Session, and not to drive for at least 24 hours after taking MDMA
    12. Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant
    13. Have a supportive relative, spouse, close friend or other caregiver not participating in this study who can serve as your emergency contact
    14. Agree to inform the researchers within 48 hours of any medical conditions and procedure
    15. Agree to not participate in any other clinical trials during this study

Exclusion criteria

Exclusion Criteria

  • Participant with PTSD

    1. Are pregnant or could become pregnant and not using
    2. Have a history of, or a current psychotic disorder or bipolar 1 disorder or dissociative identity disorder
    3. Have a history of a medical condition that could make receiving MDMA unsafe (e.g. glaucoma, heart attack, stroke, aneurysm)
    4. Have a history of Diabetes Mellitus (Type 2) that a doctor determines is not stable
    5. Have hypothyroidism (low activity in the thyroid gland) and are not on thyroid replacement
    6. Have high blood pressure, a history of heart disease, heart failure, irregular activity in the heart or require heart medication
    7. Have liver disease with symptoms
    8. Have history of hyponatremia (when you have decreased levels of sodium in the blood, which can cause confusion, seizures, fatigue and low levels of consciousness)
    9. Have history of hyperthermia (when you have a dangerously overheated body, usually in response to hot, humid weather)
    10. Weigh less than 48 kg
    11. Have recently engaged in suicidal behaviour or had serious suicidal thoughts (this will be assessed by the study team)
    12. Require ongoing therapy with a psychiatric medication
    13. Have a current eating disorder with active purging
    14. Have current major depressive disorder with psychotic features
    15. Are a serious risk to others
    16. Have recently received Electroconvulsive Therapy (ECT)
    17. Have recently engaged in ketamine-assisted therapy or used ketamine
    18. Have current substance use disorder with physiological dependence (not including caffeine or nicotine)
    19. Have recently used "Ecstasy" (material represented as containing MDMA)
    20. Are not able to give adequate
    21. Are not able to adhere to the requirements for procedures, attendance and timing of visits, and observe limits regarding study staff time and support as indicated by a time-limited clinical trial
    22. Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders
  • Close Significant Other

    1. Meet criteria for PTSD
    2. Are pregnant or could become pregnant and not using birth control
    3. Have a history of, or a current psychotic disorder or bipolar 1 disorder or dissociative identity disorder
    4. Have a history of a medical condition that could make receiving MDMA unsafe (e.g. glaucoma, heart attack, stroke, aneurysm)
    5. Have a history of Diabetes Mellitus (Type 2) that a doctor determines is not stable
    6. Have hypothyroidism (low activity in the thyroid gland) and are not on thyroid replacement
    7. Have high blood pressure, a history of heart disease, heart failure, irregular activity in the heart or require heart medication
    8. Have liver disease with symptoms
    9. Have history of hyponatremia (when you have decreased levels of sodium in the blood, which can cause confusion, seizures, fatigue and low levels of consciousness)
    10. Have history of hyperthermia (when you have a dangerously overheated body, usually in response to hot, humid weather)
    11. Weigh less than 48 kg
    12. Have recently engaged in suicidal behaviour or had serious suicidal thoughts (this will be assessed by the study team)
    13. Require ongoing therapy with a psychiatric medication
    14. Have a current eating disorder with active purging
    15. Have current major depressive disorder with psychotic features
    16. Are a serious risk to others
    17. Have recently received Electroconvulsive Therapy (ECT)
    18. Have recently engaged in ketamine-assisted therapy or used ketamine
    19. Have current substance use disorder with physiological dependence (not including caffeine or nicotine)
    20. Have recently used "Ecstasy" (material represented as containing MDMA)
    21. Are not able to give adequate informed consent
    22. Are not able to adhere to the requirements for procedures, attendance and timing of visits, and observe limits regarding study staff time and support as indicated by a time-limited clinical trial
    23. Are currently engaged in compensation litigation whereby financial gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    MDMA-Assisted CBCT Condition

    Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered in two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.

    Drug: MDMA assisted psychotherapy

  • Active comparator
    CBCT-Only Condition

    Dyads will undergo a 7-week course of CBCT psychotherapy for PTSD. Dyads who have undergone the CBCT-Only condition will have the option to do a crossover and have the two MDMA sessions after follow-up.

    Behavioral: Psychotherapy

Interventions

  • DrugMDMA assisted psychotherapy

    This treatment combines MDMA with a well researched treatment for PTSD for dyads known as CBCT. Dyads will undergo a 7-week course of psychotherapy with two doses of MDMA will be used as an adjunct to psychotherapy.

    Also known as: MDMA-assisted CBCT

  • BehavioralPsychotherapy

    A manualized treatment for PTSD for dyads wherein one person has symptoms of PTSD. This intervention is 7-week course of psychotherapy that is designed to simultaneously improve PTSD symptoms and relationship functioning through education and skill training.

    Also known as: CBCT

06

What researchers measure

Primary outcomes

  1. Feasibility of Intervention Measure (FIM)

    The Feasibility of Intervention Measure (FIM) is a self-report questionnaire in which respondents indicate the extent to which they believe that the treatment can be delivered in a given setting. Respondents indicate their responses on a five-point Likert-type (1=completely disagree, 5= completely agree).

    Time frame: 3-Month Follow-up

  2. Safety of Intervention

    Safety will be assessed by examining the frequency and severity of adverse events (AEs), serious AEs (SAEs), treatment emergent AES (TEAEs), and AEs of special interest. Participants are asked to report any AEs, SAEs, TEAEs, and AEs of special interest as they happen and during any communication with the therapist or independent assessor.

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  3. Intervention Appropriateness Measures (IAM)

    Intervention Appropriateness Measures (IAM) is a self-report measure of the perceived fit, relevance, or compatibility of an intervention. Respondents record their answers on a five-point Likert-type scale (1=completely disagree, 5= completely agree).

    Time frame: 3-month follow-up

  4. Long Term Follow-Up Questionnaire (LTFUQ)

    The Long Term Follow-Up Questionnaire (LTFUQ) is a self-report measure that assesses the long-term benefits and harms of MDMA-assisted therapy.

    Time frame: 3-Month Follow-up

  5. Clinician Administered PTSD Scale (CAPS-5)

    The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

Secondary outcomes

  1. Posttraumatic Stress Disorder Checklist for the DSM-5 (PCL-5)

    PTSD Checklist for the DSM-5 (PCL-5) is a self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD. Participants indicate how much distress they have experienced due to symptoms on a five-point Likert-type scale (1 = not at all, 5 = extremely). The total PCL-5 score (a sum of all 20 items) provides an index of overall PTSD symptom severity with higher scores indicating higher severity.

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  2. Quality of Relationships Inventory (QRI)

    The Quality of Relationships Inventory (QRI) is a self-report questionnaire that uses the role of situational, intrapersonal, and interpersonal in social support processes to assess supportive and conflictual aspects of close non-intimate relationships.

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  3. Couple Satisfaction Index (CSI)

    The Couple Satisfaction Index (CSI) is a self-report questionnaire that measures intimate relationship functioning. Respondents answer most of the questions on a six-point Likert-type scale (0= never, 5= all the time) and one question on a seven-point Likert-type scale ( 0= extremely unhappy, 6= perfect).

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  4. Patient Health Questionnaire-9 (PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) is used to assess depressive symptom severity. The PHQ-9 includes items which correspond with the diagnostic criteria for DSM-IV major depressive disorder. Scores can indicate either no depression, minimal, mild, moderate, moderately severe, or severe depression. Higher scores indicate higher severity in depressive symptoms.

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

Other outcomes

  1. Posttraumatic Growth Inventory (PTGI)

    The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life.

    Time frame: Baseline (enrolment) to Follow-up (3 month follow-up)

  2. Self-Compassion Scale-Short Form (SCS-SF)

    The Self-Compassion Scale-Short Form (SCS-SF) is a 12-item self-report measures that assess self-compassion. This measure is comprised of the following subscales: self-kindness, self-judgement, common humanity, isolation, mindfulness, and over-identification. Respondents answer questions on a five-point Likert-type scale (1= almost never, 5= almost always).

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  3. Brief Experiential Avoidance Questionnaire (BEAQ)

    The Brief Experiential Avoidance Questionnaire (BEAQ) is a 15-item self-report measure that assesses experiential avoidance. Respondents rate the extent to which they agree with each item on a six-point Likert-type scale (1 = strongly disagree, 6= strongly agree).

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  4. Alcohol Use Disorders Identification Test (AUDIT), Cannabis Use Disorders Identification Test-Revised (CUDIT-R), and Drug Use Disorders Identification Test (DUDIT)

    The Alcohol Use Disorders Identification Test (AUDIT), Cannabis Use Disorders Identification Test-Revised (CUDIT-R), and Drug Use Disorders Identification Test (DUDIT) are self-report questionnaires that assess alcohol and substance use.

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  5. Brief Posttraumatic Cognitions Inventory (PTCI-9)

    The Brief Posttraumatic Cognitions Inventory (PTCI-9) is a nine-item self-report questionnaire that measures appraisals related to trauma. Respondents answer the questionnaire on a seven-point Likert-type scale (1= totally disagree, 7= totally agree).

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  6. MOS Social Support Survey (MOS-SSS)

    The MOS Social Support Survey (MOS-SSS) is a 20-item multidimensional self-report questionnaire that assess perceived availability of social support. Respondents answer questions on a seven-point Likert-type scale (1 = none of the time, 7= all of the time), where higher score indicate greater levels of available social support.

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  7. Significant Others' Responses to Trauma Scale (SORTS)

    The Significant Others' Responses to Trauma Scale (SORTS) is a 14-item self-report questionnaire that measures relationship problems and the psychological distress of partners of people with PTSD. Respondents answer questions on a five-point Likert scale (0-4).

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  8. Modified Experiences in Close Relationships (ECR-M16)

    The Modified Experiences in Close Relationships (ECR-M16) is a 16-item self-report questionnaire that assesses attachment style. Half of the items on the scale measure attachment anxiety and the other half measures attachment avoidance. Respondents answer questions on a seven-point Likert-type scale (1= disagree, 7=agree).

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  9. Psychological Insights Questionnaire (PIQ)

    The Psychological Insights Questionnaire (PIQ) is a a 23-item self-report measure that assesses acute experiences of insight (i.e., beliefs, memories, emotions, etc.). Respondents answer questions on a six-point Likert-type scale (0= no, not at all; 5= extremely).

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  10. Mystical Experiences Questionnaire (MEQ30)

    The Mystical Experiences Questionnaire (MEQ30) is a 30-item self-report questionnaire that assesses discrete mystical experiences. Respondents rate the extent to which the experience mystical feeling, positive mood, transcendence of space/time, and ineffability on a five-point Likert-type scale (0= no/not at all, 4= extreme).

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  11. Columbia-Suicide Severity Rating Scale (C-SSRS)

    The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-administered measure of suicidal behaviour devised to detect potential suicidal thoughts or behaviours. It is designed to assess suicidal ideation, ideation intensity, and behaviour.

    Time frame: Baseline (enrolment) to Follow-up (3-month follow-up)

  12. Credibility Expectancy Questionnaire (CEQ)

    The Credibility Expectancy Questionnaire (CEQ) is a six-item self-report measure of beliefs about treatment credibility and expectancy of treatment outcomes. The some questions on the questionnaire are answered on a scale ranging from 1 (not at all) to 9 (very much) and that others are answered on a scale ranging from 0 (not at all) to 100% (very much).

    Time frame: Baseline (enrolment)

  13. Working Alliance Inventory-Observer Form (WAI-O)

    The Working Alliance Inventory-Observer Form (WAI-O) is a 36-item observer-rated measure of the alliance between a therapist and client. Observers rate each item on a scale from 1 (Never applies to the dyad) to 7 (Always applies to the dyad).

    Time frame: First therapy session, Mid-point, and Follow-up (3-month follow-up)

07

Study locations

1 of 1 sites recruiting
  • Remedy Institute
    Toronto, Ontario M6G 1L5, Canada
    Recruiting
    • Hajara Abdirahman, BS · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's planned 28 months is above that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Sep 21, 2023
StartActual
Nov 15, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06044675
Lead sponsor
Remedy
Collaborators
Remedy Institute
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Nov 15, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Song Ge
Contact
research@remedyinstitute.ca
4372914747
Anne Wagner, C.Psych.
Contact
dr.wagner@remedyinstitute.ca
647-362-8822 ext. 102
Paul Uy, MD
principal investigator · Remedy Institute
Anne Wagner, PhD
study chair · Remedy Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion